Boston Scientific Corporation (BSX)

NYSE: BSX · Real-Time Price · USD
100.72
+0.15 (0.15%)
At close: Oct 31, 2025, 4:00 PM EDT
100.82
+0.10 (0.10%)
After-hours: Oct 31, 2025, 7:59 PM EDT
0.15%
Market Cap149.24B
Revenue (ttm)19.35B
Net Income (ttm)2.79B
Shares Out 1.48B
EPS (ttm)1.87
PE Ratio53.86
Forward PE30.38
Dividendn/a
Ex-Dividend Daten/a
Volume7,273,556
Open100.41
Previous Close100.57
Day's Range99.94 - 101.15
52-Week Range83.38 - 109.50
Beta0.61
AnalystsStrong Buy
Price Target124.53 (+23.64%)
Earnings DateOct 22, 2025

About BSX

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices ... [Read more]

Sector Healthcare
IPO Date May 18, 1992
Employees 53,000
Stock Exchange NYSE
Ticker Symbol BSX
Full Company Profile

Financial Performance

In 2024, Boston Scientific's revenue was $16.75 billion, an increase of 17.61% compared to the previous year's $14.24 billion. Earnings were $1.85 billion, an increase of 18.03%.

Financial Statements

Analyst Summary

According to 19 analysts, the average rating for BSX stock is "Strong Buy." The 12-month stock price target is $124.53, which is an increase of 23.64% from the latest price.

Price Target
$124.53
(23.64% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Baron Health Care Fund Q3 2025 Top Contributors And Detractors

Argenx SE is a biotechnology company best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions. RadNet, Inc. is the largest operator of outpatient diagno...

Other symbols: ARGXINSMISRGLLYRDNT
4 days ago - Seeking Alpha

Boston Scientific Q3: Operational Improvements Warrant An Upgrade To A Buy

Boston Scientific delivered strong Q3 results, with 20% revenue growth and beats on both top and bottom lines, prompting a rating upgrade to Buy. BSX's cardiovascular and MedSurg segments, driven by i...

8 days ago - Seeking Alpha

These Analysts Increase Their Forecasts On Boston Scientific After Upbeat Earnings

Boston Scientific Corporation (NYSE:BSX) reported better-than-expected third-quarter results on Wednesday.

8 days ago - Benzinga

Boston Scientific Corporation (BSX) Q3 2025 Earnings Call Transcript

Boston Scientific Corporation (NYSE:BSX) Q3 2025 Earnings Call October 22, 2025 8:00 AM EDT Company Participants Lauren Tengler - Director of Investor Relations Michael Mahoney - Chairman, President ...

9 days ago - Seeking Alpha

Boston Scientific lifts annual profit forecast on strong demand for heart devices

Boston Scientific raised its annual profit forecast on Wednesday, after the medical device maker beat third-quarter profit estimates on strong demand for its heart devices.

9 days ago - Reuters

Boston Scientific Raises Outlook on Continued Cardiovascular Growth

The medical device company recorded higher third-quarter sales and raised its full-year earnings guidance on the back of continued growth in its cardiovascular segment.

9 days ago - WSJ

Boston Scientific announces results for third quarter 2025

MARLBOROUGH, Mass. , Oct. 22, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.065 billion during the third quarter of 2025, growing 20.3 percent on a reported ...

9 days ago - PRNewsWire

It's time to scoop up undervalued stocks in this critical sector of the economy

Expanding your horizons and considering neglected sectors can help you identify bargain opportunities while defending your investment portfolio from a stock-market decline.

10 days ago - Market Watch

Boston Scientific buys Nalu Medical for $533 million

Medical device maker Boston Scientific said on Friday it will buy privately-held Nalu Medical for a cash payment of about $533 million, expanding its portfolio to address chronic pain.

14 days ago - Reuters

Boston Scientific Announces Agreement to Acquire Nalu Medical, Inc.

Acquisition to expand the neuromodulation offerings for people living with chronic pain MARLBOROUGH, Mass. , Oct. 17, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it ...

14 days ago - PRNewsWire

9 Stocks to Buy Before Their Earnings Reports

Stocks like Adobe and Okta have room to climb if their earnings beat expectations.

Other symbols: ADBECSCOGMOKTAZM
18 days ago - Barrons

4 Top AI-Powered Healthcare Stocks

Healthcare stocks quietly outperformed the market in the past 30 days as headlines centered on the government shutdown over the extension of Affordable Care Act tax credits for 2026. The AI in healthc...

Other symbols: OPRXVEEVZEPP
22 days ago - Seeking Alpha

Boston Scientific Corporation (BSX) Analyst/Investor Day Transcript

Boston Scientific Corporation (NYSE:BSX) Analyst/Investor Day September 30, 2025 8:30 AM EDT Company Participants Lauren Tengler - Director of Investor Relations Michael Mahoney - Chairman, President...

4 weeks ago - Seeking Alpha

Top 3 Health Care Stocks That May Explode In September

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: ATYRRVPH
6 weeks ago - Benzinga

Boston Scientific announces 2025 Investor Day meeting and conference call discussing third quarter 2025 results

MARLBOROUGH, Mass. , Sept. 2, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will host a meeting with the investor community to review its financial goals and long-term growth strategi...

2 months ago - PRNewsWire

8 Growth Stocks to Buy That Aren't Technology. What Makes Them Worth It.

As tech stocks float at historic highs, it's a good time to look elsewhere for growth. A Citi screen turned up eight names that are mostly outside the tech sector.

Other symbols: COFUBER
2 months ago - Barrons

Boston Scientific Corporation Is Expensive But Worth It

Boston Scientific is a 'forever stock' due to management foresight, robust R&D, and leadership in AI-driven medical devices. Despite a weak valuation grade, its strong financials, global expansion, an...

2 months ago - Seeking Alpha

Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025

We added key positions in Masimo, Exact Sciences, Eli Lilly, Penumbra, and Edwards Lifesciences, each with strong growth drivers and market leadership. Our investment in Masimo is supported by divesti...

3 months ago - Seeking Alpha

Former FDA Director and Boston Scientific Leaders Join Keyron Ahead of Human Trials of First Device with Metabolic Surgery-Like Results Without Incisions

LONDON & BOSTON--(BUSINESS WIRE)--Keyron appoints former FDA and Boston Scientific leaders as ForePass—a breakthrough device for severe metabolic disease—prepares for clinical trials.

3 months ago - Business Wire

10 stocks favored to gain up to 30% in a sector that has missed this year's rally

All but two of the S&P 500's sectors are up so far in 2025.

3 months ago - Market Watch

Boston Scientific Corporation (BSX) Q2 2025 Earnings Call Transcript

Boston Scientific Corporation (NYSE:BSX) Q2 2025 Earnings Conference Call July 23, 2025 8:00 AM ET Company Participants Jonathan R. Monson - Executive VP & CFO Kenneth M.

3 months ago - Seeking Alpha

Cramer's Stop Trading: Boston Scientific

Jim Cramer breaks down why he's keeping an eye on shares of Boston Scientific.

3 months ago - CNBC Television

Boston Scientific lifts annual profit view on steady heart devices demand

Boston Scientific raised its annual profit forecast on Wednesday, after strong demand for its heart devices helped the U.S. medical device maker beat second-quarter profit estimates.

3 months ago - Reuters

Boston Scientific announces results for second quarter 2025

MARLBOROUGH, Mass. , July 23, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.061 billion during the second quarter of 2025, growing 22.8 percent on a reported...

3 months ago - PRNewsWire

How To Trade Boston Scientific Stock Ahead Of Its Upcoming Earnings?

Boston Scientific (NYSE:BSX) is set to announce its earnings on Wednesday, July 23, 2025. In the last five years, BSX stock has shown a positive return on the day after earnings announcements in 60% o...

3 months ago - Forbes